@article {Wang2020.05.01.20086421, author = {Jingrong Wang and Xingqi Dong and Boting Zhang and Xinping Yang and Zhi Li and Xicheng Wang and Shuguang Zuo}, title = {Characteristics of lymphocyte subsets and their predicting values for the severity of COVID-19 patients}, elocation-id = {2020.05.01.20086421}, year = {2020}, doi = {10.1101/2020.05.01.20086421}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Severe COVID-19 patients showed worse clinical outcomes compared to mild and moderate patients. However, effective indicators are still lacking to predict the severity of the disease. In the present study, we retrospectively analyzed the clinical and laboratory data of 16 COVID-19 patients and found that the absolute counts of three T-cells (CD3+, CD4+, and CD8+) were significantly lower in the moderate and severe patients than those in mild patients and were significantly lower in severe patients than in moderate patients on admission. With the recovery of the COVID-19, serum levels of inflammatory biomarkers (CRP, PCT, and IL6) of moderate and severe patients gradually decreased. In contrast, the counts of lymphocytes and their subsets including CD3+, CD4+, and CD8+ T cells gradually increased in severe patients, and eventually showed comparable levels with moderate patients. ROC analysis showed that the counts of CD3+, CD4+, and CD8+ T-cells with AUC \> 0.9 have potential values for predicting the severity of COVID-19 patients. In conclusion, the reduction of CD3+, CD4+, and CD8+ T-cells is related to the severity of COVID-19 and dynamic detection of these T-lymphocyte subsets may help predict the outcome of the patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported financially by New Product Development Projects of Yunnan Province (2016BC005), The {\textquotedblleft}Thirteenth Five-Year{\textquotedblright} Science and Technology Major Project for Prevention and Control of AIDS, Viral Hepatitis and Other Major Infectious Diseases (2017ZX10202101-002-005) and the National Natural Science Foundation of China (8136024).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/05/12/2020.05.01.20086421}, eprint = {https://www.medrxiv.org/content/early/2020/05/12/2020.05.01.20086421.full.pdf}, journal = {medRxiv} }